03/20/2026

[Duplicate] Recent Oncology Related FDA Approvals and Expanded Indications

FDA Approves AstraZeneca's new treatment regimen for Calquence (acalabrutinib) in combination with Venetoclax for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

FDA Approves Boehringer Ingleheim's HERNEXEOS (zongertinib tablets), for adults with HER2-mutant advanced NSCLC as an initial treatment option

More Info